Estrogen-Only Menopause Therapy Linked to Lower Dementia Risk

Estrogen-only menopausal hormone therapy is associated with a lower risk of developing Alzheimer’s disease and related dementias in older women, according to a Stanford Medicine study. Researchers analyzed health records and found a distinct cognitive benefit for patients using estrogen formulations, though experts caution the findings do not prove direct causality.

Stanford Medicine Findings on Estrogen Therapy

According to Stanford Medicine researchers, estrogen-only menopausal hormone therapy (MHT) correlates with a reduced risk of Alzheimer’s disease. The study adjusted for factors such as education and race, isolating the impact of the hormone treatment. By age 60, more than 30% of women have undergone hysterectomies and no longer possess a uterus, making estrogen-only treatment the clinically recommended approach for this demographic.

Study Demographics and Formulation Limits

The study participants skewed older, with an average age of 70 years, and many had previously undergone hysterectomies. Consequently, the vast majority of participants relied on oral estrogen-only regimens. Researchers could not obtain conclusive autopsy findings regarding dementia risk for women using estrogen-plus-progestin formulations due to an insufficient sample size of autopsied patients on that specific combination. Furthermore, topical estrogen-only users were excluded from the primary count, restricting the applicability of the results strictly to oral estrogen-only formulations.

Contrasting Historical Data and Clinical Recommendations

The new findings challenge previous medical consensus established in the wake of the 2003 Women’s Health Initiative Memory Study. That large-scale analysis indicated that estrogen-plus-progestin formulations increased dementia risk and linked the combination to higher rates of breast cancer and heart disease. While the U.S. Food and Drug Administration removed a black-box warning regarding these therapies in 2025, public concern following the 2003 report caused lifetime usage estimates of MHT to plummet from roughly 27% down to below 5%, according to Hosseini. Co-researcher Dr. Victor Bruno pointed out that the new data runs counter to long-standing clinical advice telling patients to avoid MHT for memory decline.

Future Research and Causal Limitations

Despite the clear statistical association between estrogen-only therapy and reduced Alzheimer’s risk, investigators emphasize that the study does not provide definitive proof of causality. Past studies investigating MHT have yielded conflicting results due to varying patient age ranges at the start of therapy, divergent clinical outcomes, and differences in formulation routes and durations. Researchers note that because the women in the Stanford study initiated therapy at an older age, the actual protective benefits of early MHT initiation may be even higher than currently recorded.